MYCL proto-oncogene, bHLH transcription factor (MYCL)

MYCL proto-oncogene, bHLH transcription factor (MYCL, also known as L-Myc) encodes a nuclear transcription factor of the basic helix-loop-helix family, involved in regulating gene expression by binding specific DNA sequences and modulating RNA polymerase II-dependent transcription. It is a member of the MYC proto-oncogene family, distinct for its molecular properties and superior efficacy in inducing pluripotency compared to other MYC proteins. MYCL plays a major role in cancer biology—its amplification, overexpression, or functional variants drive tumor cell proliferation, migration, and invasion in several malignancies, notably lung cancer and Merkel cell carcinoma. It interacts with other transcriptional regulators (e.g., MAX) and, depending on context, may serve as a biomarker for risk stratification or prognosis, particularly when evaluating genetic polymorphisms or expression levels in various cancer types. While MYCL remains a promising therapeutic target, direct pharmacological interventions are still in preclinical stages and complicated by safety and selectivity constraints

Other names

L-MycLMYCbHLHe38MYCL1L-Myc-1 proto-oncogeneProtein L-MycV-myc myelocytomatosis viral oncogene homologl-myc proteinmyc-related gene from lung canceroncogene lmycClass E basic helix-loop-helix protein 38protein L-Myc-1v-myc avian myelocytomatosis viral oncogene lung carcinoma derived homologv-myc myelocytomatosis viral oncogene homolog 1 (lung carcinoma derived)BHLHE38

No approved direct MYCL-targeted drugs currently exist; targeting is under investigation. Mechanisms explored in experimental settings include gene silencing, inhibition of transcriptional activity, or altering protein-protein interactions.